Rallybio (RLYB) Capital Expenditure: History & Chart

Rallybio Corporation(RLYB)

Biotechnology · New Haven, CT

$17.08+0.18 (+1.07%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Rallybio Corporation

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.

New Haven, CT

7 employees

www.rallybio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stephen Uden

View full financials

Capital Expenditures

The latest quarterly capex is $0. Capital Expenditures (CapEx) represents spending on physical assets like property, plant, equipment, and technology infrastructure. It's the investment in the company's future productive capacity.

Q2 FY2026 (2026-06-30).

Depreciation|PP&E|Free Cash Flow|Acquisitions|Cash Flow

CapEx

RLYB CapEx

$0.00

Reported quarterly capital expenditures; no daily interpolation. Q2 FY2026 (2026-06-30): $0.00.

+100.00% over 10Y

Current CapEx

Q2 FY2026 · 2026-06-30

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly CapEx History

Period	CapEx	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$0	N/A	N/A
Q1 FY2026Period end 2026-03-31	$0	N/A	N/A
Q4 FY2025Period end 2025-12-31	$0	N/A	N/A
Q3 FY2025Period end 2025-09-30	$0	N/A	N/A
Q2 FY2025Period end 2025-06-30	$0	N/A	N/A
Q1 FY2025Period end 2025-03-31	$0	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-30	$0	N/A	N/A
Q2 FY2024Period end 2024-06-30	$0	N/A	N/A
Q1 FY2024Period end 2024-03-31	$0	N/A	N/A
Q4 FY2023Period end 2023-12-31	−$12.00K	-290.88%	N/A
Q3 FY2023Period end 2023-09-30	−$3.07K	N/A	+23.25%
Q2 FY2023Period end 2023-06-30	$0	N/A	N/A
Q1 FY2023Period end 2023-03-31	$0	N/A	N/A
Q4 FY2022Period end 2022-12-31	$0	N/A	N/A
Q3 FY2022Period end 2022-09-30	−$4.00K	+71.43%	+96.92%
Q2 FY2022Period end 2022-06-30	−$14.00K	+61.11%	-250.00%
Q1 FY2022Period end 2022-03-31	−$36.00K	+73.72%	+41.94%
Q4 FY2021Period end 2021-12-31	−$137.00K	-5.38%	-29.25%
Q3 FY2021Period end 2021-09-30	−$130.00K	-3150.00%	-465.22%
Q2 FY2021Period end 2021-06-30	−$4.00K	+93.55%	+33.33%
Q1 FY2021Period end 2021-03-31	−$62.00K	+41.51%	-3000.00%
Q4 FY2020Period end 2020-12-31	−$106.00K	-360.87%	N/A
Q3 FY2020Period end 2020-09-30	−$23.00K	-283.33%	N/A
Q2 FY2020Period end 2020-06-30	−$6.00K	-200.00%	N/A
Q1 FY2020Period end 2020-03-31	−$2.00K	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026